ISSUE 99 I OCTOBER 2020

In association with

under the

microscope

As factory inspections resume, what can manufacturers do to ensure they are up to scratch?

Oxytocin: Could love be a drug? 

AI-enabled risk detection

Disrupting the fertility sector

Oxytocin: Could love be a drug?

AI-enabled risk detection

Disrupting the fertility sector
09/23/2020 10:35:58
  • Home | Under the microscope
  • In this issue
  • SHL Medical Company Insight
  • SHL Medical
  • Contents
  • Mimotopes
  • News
  • VEGA Australia
  • Covid-19 executive briefing by GlobalData
  • Wipotec
  • Nasal spray vaccine for Covid-19
  • Datwyler Company Insight
  • Datwyler
  • Covid-19 clinical trials continue to rise in Brazil
  • Biogazelle
  • AstraZeneca’s Phase I / II Covid-19 vaccine trial
  • Swiftpak
  • MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1
  • Biesterfeld
  • The pharma industry briefing
  • From antitoxins to Covid-19 drugs: charting the history of antibody drugs
  • Quality control: pharma manufacturing inspections explained
  • Molnár-Institute Company Insight
  • Molnar-Institute
  • Oxytocin: the therapeutic potential of the ‘love hormone’
  • AI-enabled risk detection in pharma manufacturing
  • Dr. Paul Lohmann
  • Addressing the long-term effects of Covid-19
  • Eyes on the prize: the latest in retinitis pigmentosa gene therapies
  • HOF Sonderanlagenbau Company Insight
  • HOF Sonderanlagenbau
  • Breaking the taboo: disrupting the fertility sector
  • Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?
  • Nolato Company Insight
  • Nolato
  • Pharmacovigilance case intake: why the hesitation to automate?
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Zenatek
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Events
  • Next issue